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Available online xxxxBackground: Thirty-percent of patients with epilepsy are drug-resistant, and might beneﬁt from effective nonin-
vasive therapeutic interventions. Evidence is accumulating on the efﬁcacy of autonomic biofeedback therapy
using galvanic skin response (GSR; an index of sympathetic arousal) in treating epileptic seizures. This study
aimed to extend previous controlled clinical trials of autonomic biofeedback therapy with a larger homogeneous
sample of patients with temporal lobe epilepsy. In addition, we used neuroimaging to characterize neural
mechanisms of change in seizure frequency following the therapy.
Methods: Forty patients with drug-resistant temporal lobe epilepsy (TLE) (age: 18 to 70 years old), on stable
doses of anti-epileptic medication, were recruited into a controlled and parallel-group trial from three screening
centers in the UK. Patients were allocated to either an active intervention group, who received therapy with GSR
biofeedback, or a control group, who received treatment as usual. Allocation to the group was informed, in part,
by whether patients could travel to attend repeated therapy sessions (non-randomized). Measurement of out-
comes was undertaken by an assessor blinded to the patients' group membership. Resting-state functional and
structural MRI data were acquired before and after one month of therapy in the therapy group, and before and
after a one-month interval in the control group. The percentage changeof seizure frequencywas theprimary out-
come measure. The analysis employed an intention–to–treat principle. The secondary outcome was the change
in default mode network (DMN) and limbic network functional connectivity tested for effects of therapy. The
trial was registered with the National Institute for Health Research (NIHR) portfolio (ID 15967).
Findings: Data were acquired between May 2014 and October 2016. Twenty participants were assigned to
each group. Two patients in the control group dropped out before the second scan, leaving 18 control partici-
pants. There was a signiﬁcant difference in reduction of seizure frequency between the therapy and control
groups (p b 0.001: MannWhitney U Test). The seizure frequency in the therapy group was signiﬁcantly reduced
(p b 0.001:Wilcoxon Signed Rank Test) following GSR biofeedback, with a mean seizure reduction of 43% (SD=
± 32.12, median =−37.26, 95% CI -58.02% to−27.96%). No signiﬁcant seizure reduction was observed in the
control group, with a mean increase in seizure frequency of 31% (SD = ±88.27, median = 0, 95% CI−12.83%
to 74.96%). The effect size of group comparison was 1.14 (95% CI 0.44 to 1.82). 45% of patients in the therapy
group showed a seizure reduction of N50%. Neuroimaging analysis revealed that post-therapy seizure reduction
was linearly correlated with enhanced functional connectivity between right amygdala and both the
orbitofrontal cortex (OFC) and frontal pole (FP).
Interpretation:Our clinical study provides evidence for autonomic biofeedback therapy as an effective and potent
behavioral intervention for patients with drug-resistant epilepsy. This approach is non-pharmacological, non-
invasive and seemingly side-effect free.
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Fig. 1. Biofeedback setting. An animation moves forward with increase in skin
conductance and backward with decrease in skin conductance.
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The autonomic nervous system is crucial for maintenance of homeo-
static control of the internal state of the body and interacts closely with
central nervous system through interoceptive feedback (Jänig, 2008). In
epilepsy, the autonomic nervous system is usually considered in relation
to differential diagnoses (e.g. syncope) or in the context of Sudden Unex-
pected Death (SUDEP). Its contribution, and its central regulation, to the
generation and suppression of epileptic seizures are largely overlooked.
Penﬁeld and Jasper (1954) showed that normal and abnormal
supratentorial brain activity, including focal epileptic activity, can differ-
entially inﬂuence autonomic function. Animal models show that single
spike activity can alter the discharge of cardiac autonomic neurons
(Schraeder and Celesia, 1977) and that ictal tachycardia signiﬁcantly
modulates both sympathetic and parasympathetic activities (Sevcencu
et al., 2016). Patientswith epilepsy canmanifest autonomic abnormalities
even between seizure events, including abnormal measures of sympa-
thetic (galvanic skin response [GSR]) and parasympathetic (heart rate
variability [HRV]) function (Drake et al., 1998; Evrengül et al., 2005).
Acute autonomic dysfunction originating in epileptic activity is implicated
as the likely pre-terminal mechanism for SUDEP (Aiba and Noebels,
2015).
The converse impact of autonomic function on epilepsy should not be
disregarded. There is a convergent evidence suggesting that disturbances
in autonomic activity inﬂuence the generation of seizures. Surveys in-
volving large patient samples identify emotional stress, tiredness, and
sleep deprivation, each associated with transient autonomic dysregula-
tion, as the top three triggers of seizures (Pinikahana and Dono, 2009;
Nakken et al., 2005). Psychological states can dysregulate autonomoic
control; for example perseverative cognition (worry and rumination) is
associated with sympathetic–parasympathetic imbalance reﬂected in
abnormal HRV (Ottaviani et al., 2015). Visceral afferent feedback of (dys-
regulated) physiological state inﬂuences the activation of ascending
neuromodulator pathways (Critchley and Harrison, 2013). Direct stimu-
lation of the vagus nerve can abort ongoing seizure activity, perhaps
through re-regulated (regimented) autonomic afferent signaling. De-
spite both direct and circumstantial evidence indicating that autonomic
nervous system function is closely linked to the generation of epileptic
seizures, the pathophysiological mechanisms underpinning this associa-
tion are poorly understood.
We reported (Nagai et al., 2004a; Nagai et al., 2009) investigation
into the relationship between peripheral sympathetic activity (mea-
sured using GSR) and central cortical excitation (an experimentally-
induced slow cortical potential, measured using EEG). GSR reﬂects ac-
tivity of sympathetic nervous innervation to skin sweat glands and is
a sensitive index of psychophysiological arousal. We demonstrated an
inverse relationship between peripheral and central arousal: height-
ened peripheral sympathetic arousal (increased skin conductance) pro-
voked a decrease in cortical excitation (reduction in slow cortical
potential), observed both in healthy participants (Nagai et al., 2004a)
and people with epilepsy (Nagai et al., 2009). Crucially, GSR can be
modulated non-invasively using biofeedback. GSR has the advantage
of being an accessible (hence easy-to-measure) autonomic parameter,
which is exclusively coupled to the sympathetic nervous system. In
GSR biofeedback, patients are trained to control their physiological re-
sponses through visual and auditory feedback (Fig. 1). The ﬁrst fully
randomized controlled trial of structured GSR biofeedback training in
patients with drug- resistant epilepsy elicited a reduction in seizure
frequency of 50% ormore in 60% of patients allocated to the active ther-
apy group (Nagai et al., 2004b). In parallel to our current work, the
efﬁcacy of GSR biofeedback is supported by ﬁndings of recent indepen-
dent studies, drawing from our group's earlier published works
(Micoulaud-Franchi et al., 2014; Kotwas et al., 2017). The clinical bene-
ﬁt of GSR biofeedback therapy can persist over time: a subset of patients
who kept over four years of seizure records demonstrated no apparent
re-increase after N50% seizure reduction (Nagai and Trimble, 2014).Please cite this article as: Nagai, Y., et al., Epileptic Seizures are Reduced b
limbic Connectivity: A Controlled Tr..., EBioMedicine (2017), https://doi.oFunctional neuroimaging, undertaken to identify neural substrates en-
gaged during performance of GSR biofeedback, highlighted an inverse
coupling between activity within ventral medial and orbital frontal cor-
tical regions (ventral MPFC/OFC) and GSRmeasures of peripheral sym-
pathetic tone (Nagai et al., 2004c).
These clinical and neuroimaging observations suggest a potential
mechanism through which longer term therapeutic training using auto-
nomic biofeedback might impact on frontolimbic neurocircuitry,
supporting both the tonic regulation of internal bodily arousal and the
triggering of epileptic seizureswithin connectedmesial temporal centers.
In patients with epilepsy, functional neural connectivity is of key rele-
vance tounderstanding seizure propagation (Lemieux et al., 2011). Corre-
spondingly, ‘constitutional’ abnormalities in network connectivity,
notably impaired couplingwithin the defaultmodenetwork, are reported
in patients with epilepsy (Kay et al., 2013). Animal models of temporal
lobe epilepsy engender disruption of functional brain networks, including
dysconnectivitywithin the defaultmode network (DMN) and limbic net-
works (Gill et al., 2017). TheDMN, one of themost reproducible networks
of functional connectivity, encompasses precuneus, medial prefrontal, in-
ferior parietal andmedial temporal cortices (Raichle et al., 2001); activity
across these regions is typically greater at rest and during self-referential
processing (thinking about oneself), and decreases when an individual
engages in an external task. DMN dysfunction is associated with loss of
consciousness (Danielson et al., 2011). Given the previous observation
of frontal control over sympathetic activity and limbic involvement of
pathological and emotional impact on temporal lobe epilepsy, we inves-
tigated changes in frontolimbic functional network connectivity which
may underlie the therapeutic effects of autonomic biofeedback training
to reduce seizures in patients with drug-resistant epilepsy. The current
study aimed to address the efﬁcacy of autonomic biofeedback in a larger
clinical sample of 40 patients with drug-resistant temporal lobe epilepsy
and to understand further, using neuroimaging, neural mechanisms
supporting seizure reduction.We tested the prediction that intrinsic rest-
ing state network connectivity, particularly between DMN and limbic
networks, predicted improvement in seizure frequency in this patient
group.
2. Materials and Methods
2.1. Study Design and Participants
We conducted a controlled, single-blinded, single-center trial,
recruiting patients from three screening sites in the UK andy Autonomic Biofeedback Therapy Through Enhancement of Fronto-
rg/10.1016/j.ebiom.2017.12.012
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(either cryptogenic or symptomatic), aged between 18 and 70 years
participated in the study. Each patient had a diagnosis and EEG evidence
of TLE, a clinical history lasting more than two years, and could keep a
seizure diary. Medication was required to be unchanged for more than
twomonths before patient participated. Patientswith a history of severe
psychiatric illness, drug abuse, major head injury or signiﬁcant learning
disability were excluded. The study was approved by the clinical ethics
committee at the Health Research Authority and was registered in the
UK clinical research network. All the patients gave written informed
consent in advance of their participation in the study. The study follow-
ed the Declaration of Helsinki, following ethics regulations and
standards of good clinical practice. Data management followed strict
policies of the University of Sussex (Supplementary material, p4). The
trial was registered with the National Institute for Health Research
(NIHR) portfolio (ID 15967).
2.2. Patient Allocation and Masking
Patientswere allocated to therapy (active intervention) or to control
(treatment as usual) groups initially using a randomization table.
Consultant neurologists enrolled the patients, and group assignment
was conducted by the PI (the therapist). Allocation was then subse-
quently informed by the logistics of whether the patient was willing
to commit to attending the therapy sessions, which was heavily inﬂu-
enced by geographical location: Patients were required to travel to the
south coast of England three times a week consecutively for four
weeks. This created a deviation from the randomization by 15%. The
ethics committee was notiﬁed. Patients in the control group remained
on the samemedication (or nomedication) at a constant dose through-
out the study and were not involved in any other therapeutic interven-
tion. Although full double-blinding of behavioral studies is difﬁcult, the
assessment of behavioral outcomes (seizure frequency changes) was
undertaken by an independent assessor blinded to group membership.
To mitigate motivation bias, patients in the control group were in-
formed that they would be offered online version of therapy following
the study and all patients accepted an offer.
2.3. Procedure
Patients in the therapy and control groups recorded seizure frequen-
cy over three months before the initial neuroimaging session. In the
therapy group this was followed by the ﬁrst biofeedback training ses-
sion. During biofeedback training, GSR was recorded continuously
using dry nickel electrodes attached to the palmar surface of the non-
dominant hand of each patient, connected to Inner Tuner biofeedback
equipment and a customized version of the software (Ultrasis plc,
UK). GSR biofeedback training was performed for 30 min, three times
a week, for four weeks. Patients were asked to drive forward a digital
animation on a computer display to the best of their ability, by making
themselves more alert. Positive visual feedback (animation goes
forward) was given as the measured (GSR) sympathetic tone was
increased by the patient. Patients were encouraged to practice the ac-
quired skill (to increase sympathetic activity) between therapy sessions
by recollection of the therapy and associated sensations. Patients
continued to record their seizure frequency for three further months:
i.e. in the therapy group, three months before the start of the therapy,
during the month of active therapy, and for three months after the last
therapy session (and, in the treatment as usual group, over equivalent
periods; Supplementary Fig. S1). At the beginning and end of the
study, each patient completed standardized self-report questionnaires
probing affective symptoms (Spielberger State and Trait Anxiety, Beck
Depression Inventory, Perceived Stress Scale).
Neuroimaging experiments were performed using a 1.5T system
(Magnetom Avanto, Siemens, Erlangen, Germany), equipped with a
maximum gradient strength of 44 mTm−1, and a 32-channel headPlease cite this article as: Nagai, Y., et al., Epileptic Seizures are Reduced b
limbic Connectivity: A Controlled Tr..., EBioMedicine (2017), https://doi.ocoil. All patients underwent two identical sessions: at baseline and at
the end of the biofeedback training for the therapy group, and after a
month interval for the control group. The acquisitions of each session
are described in Supplementary material. Resting-state fMRI data
were pre-processed using SPM8 (see Supplementary material p3, 4).
2.4. Outcomes
The primary outcome of the study was the percentage change in
seizure frequency after a month of therapy course, compared to the
baseline seizure frequency. The baseline monthly seizure frequency
was calculated as an average of three months' seizure frequency prior
to the therapy. The post-therapy seizure frequency was the average of
three months' seizure frequency following the last therapy and neuro-
imaging session. In the control group the equivalent measure was the
average of the last three months of seven months of seizure recording,
following the second neuroimaging session (see Supplementary
Fig. S1). These data were acquired from patients by an independent
assessor who was blinded to group membership. The sample size was
determined by our previous study. We had observed a mean decrease
in seizure frequency of 49.3% (SD ± 41.6%) in the biofeedback active
group compared to an increase of 24.6% (SD ± 45.6%) in the sham con-
trol group. Here we expected no change in seizure frequency in the
treatment as usual group. With power and threshold of signiﬁcance
set at 90% and 5% respectively, 15 patients were necessary in each
group (study size = 30) to detect an effect size of 1.2 (difference be-
tween group = 50, SD = 42). The number of patients recruited in the
present study was therefore large enough to detect this anticipated
treatment effect.
A secondary outcome was the change in functional connectivity pu-
tatively induced by therapy focusing on the two primary networks of in-
terest, the DMN and the limbic network. In the neuroimaging context
(with functional magnetic resonance imaging; fMRI), functional con-
nectivity is deﬁned as the association of neuronal activity patterns be-
tween anatomically separated brain regions. One method to quantify
functional connectivity from fMRI datasets is seed-based analysis, in
which connectivity between regions is estimated from the correlation
betweenﬂuctuations of the hemodynamic signal (reﬂecting neural acti-
vation) within a given region (seed) and ﬂuctuations occurring in the
rest of the brain. Typically, connectivity analyses are performed on
fMRI data acquired at rest. We undertook this seed-based analysis on
task-free, resting state datasets. We selected an a priori region-of-
interest (ROI) for target networks (medial prefrontal cortex for the
DMN and amygdala for the limbic network, separately examining left
and right amygdala). We quantiﬁed functional connectivity between
each ROI and the rest of the brain for theﬁrst and second session (i.e. be-
fore and after the intervention for the therapy group; details in Supple-
mentary material).
2.5. Statistical Analysis
For the behavioral data, ﬁrst we checked the distribution of the per-
centage change in seizure frequency and conﬁrmed its non-normality. A
Wilcoxon Signed Rank Test was used to analyze the patients' mean
seizure frequency before and after therapy in the active therapy and
control groups. A Mann-Witney U test was used to explore differences
in percentage seizure frequency change between the therapy and
control groups.
For the neuroimaging data, all statistical analyses were performed
using SPM8. For each network (DMN, left amygdala network, and
right amygdala network), a ﬂexible factorial model was used to model
the effects of the group (therapy vs. control) and of time (before vs.
after intervention), and their interaction (see Supplementary material,
Seed based analysis, Figs. S3 and S4). Separate models were then used
to investigate correlations between changes in functional connectivity
and changes in seizure frequency and in psychological variables (STAI,y Autonomic Biofeedback Therapy Through Enhancement of Fronto-
rg/10.1016/j.ebiom.2017.12.012
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sons using the family-wise error (FWE)method at cluster level, forming
clusters at uncorrected level using p b 0.001. Thus, signiﬁcance is indi-
vidually ﬁrst assessed independently at each voxel, using a threshold
of p b 0.001, followed by correction for multiple comparisons, using an
FWE corrected threshold signiﬁcance of p b 0.05.
2.6. Role of Funding Source
The funding source was not involved in data collection and analysis,
interpretation of the results, nor decision to submit the manuscript for
publication.
3. Results
This clinical trial was conducted between May 2014 and October
2016. 168 patients were invited as eligible candidates from the National
Hospital for Neurology and Neurosurgery (Tertiary care center),
London, the Brighton and Sussex University Hospital, Brighton (second-
ary care center), and the St George's University Hospital (secondary care
center), London (Fig. 2): twenty-four patients agreed to take part in the
study. In addition, sixteen patients were recruited from advertisement.
Patients were allocated to either therapy + two scanning, or control
+ two scanning groups. There was no signiﬁcant difference between
the groups for age (years ± S.D.; control: 43.25 ± 11.90; therapy,
44.80 ± 15.55: p = 0.73, independent t-test), age of onset (years ±
S.D.; control: 17.60 ± 15.13; therapy, 24.10 ± 15.14: p = 0.18), dura-
tion of epilepsy (years ± S.D.; control: 26.40 ± 17.63; therapy, 20.70Fig. 2. CONSRT
Please cite this article as: Nagai, Y., et al., Epileptic Seizures are Reduced b
limbic Connectivity: A Controlled Tr..., EBioMedicine (2017), https://doi.o±15.70: p= 0.29) or baseline seizure frequency (seizures/month;me-
dian 10.84 for control, 5.36 for therapy; p = 0.09). However, we report
that the study deviated from the planned full randomization. Patients
who were not geographically close to the institution were mostly un-
able to travel to the institution three times a week for four weeks and
consequently could not commit to participating in the therapy group.
Thus, full randomization was not possible. Six patients in control
group were inﬂuenced by geographical restriction and nine patients in
biofeedback group had to travel far away up to 3 h. The demographic
characteristics of the patients at baseline are described in Table 1. All
twenty patients in the therapy group completed the training course, in-
dicating good compliance; however one patient dropped out in the
follow-up period (due to reluctance to maintain a detailed seizure re-
cord). All 20 control group patients completed the ﬁrst scanning ses-
sion; two patients dropped out due to medication changes after the
ﬁrst scanning session and one further patient chose to leave during
the follow-up period (due to medication change). Data were analyzed
on an intention-to-treat basis.
All patients in the therapy group completed autonomic biofeedback
successfully, achieving signiﬁcant increase in skin conductance (Supple-
mentary Fig. S2). There was a signiﬁcant between-group difference in
the percentage seizure reduction (p b 0.001: Mann-Witney U Test).
The therapy group had a signiﬁcant reduction in seizure frequency
after one month of intervention (p b 0.001: Wilcoxon Signed Rank
Test) with a mean seizure reduction of 43.0% (SD = ±32.12, median
= 37.26, 95% CI -58.02% to −27.96%, IQR -74.67% to −13.75%). In 9/
20 patients, there was N50% seizure reduction, representing a 45% re-
sponse rate. One patient became seizure-free. In contrast, overalldiagram.
y Autonomic Biofeedback Therapy Through Enhancement of Fronto-
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Table 1
Demographics and baseline clinical characteristics.
Therapy group (n = 20) TAU group (n = 20)
Sex
Male 10/20 (50%) 6/20 (30%)
Female 10/20 (50%) 14/20 (70%)
Age 44.80 (±15.55) years old 43.25 (±11.90) years old
Age of onset 24.10 (±15.14) years old 17.60 (±15.13) years old
Duration of
epilepsy
20.70 (±15.70) years 26.40 (±17.63) years
Medication Carbamazepine 5/20 (25%) Carbamazepine 5/20 (25%)
Clobazam 6/20 (30%) Clobazam 3/20 (15%)
Levatiracetam 7/20 (35%) Clonazepam 1/20 (5%)
Lamotorigine 5/20 (25%) Levatiracetam 5/20 (40%)
Lacosamide 1/20 (5%) Lamotorigine 8/20 (40%)
Oxcarbazepine 1/20 (5%) Oxcarbazepine 2/20 (10%)
Perampenel 5/20 (25%) Perampenel 2/20 (10%)
Phyenytoine 2/20 (10%) Prevabaline 1/20 (5%)
Pregavarine 6/20 (30%) Topiramate 1/20 (5%)
Sodium varproate 6/20
(30%)
Sodium varproate 2/20 (10%)
Zonisamizde 2/20 (10%)
Affected side
Right 10/20 (50%) 6/20 (30%)
Left 8/20 (40%) 9/20 (45%)
Not identiﬁable 2/20 (10%) 4/20 (20%)



















Marital state Single 12/20 (60%) Single 12/20 (60%)
Married 8/20 (40%) Married 8/20 (40%)
Education Primary education 3/20 (15%) Primary education 3/20 (15%)
High school education 5/20
(25%)
High school education 5/20
(25%)
College education 3/20 (15%) College education 1/20 (5%)





Not disclosed 2/20 (10%) Not disclosed 1/20 (5%)
Employment Not working 12/20 (60%) Not working 11/20 (55%)
Part time 5/20 (25%) Part time 6/20 (30%)
Full time 3/20 (15%) Full time 3/20 (15%)
5Y. Nagai et al. / EBioMedicine xxx (2017) xxx–xxxseizure frequency increased in the control group by 31.1% (SD = ±
88.27, median = 0, 95% CI −12.83% to 74.96%, IQR −17.42% to
41.56%) (Fig. 3). The observed effect size [(Therapy group mean -
Control group mean)/sample SD] was 1.14 (95% CI 0.44 to 1.82). There
was no adverse events or side effects reported through this behavioral
therapy.
We observed increases in functional connectivity compared to base-
line between MPFC (as a seed) and bilateral middle/superior frontal
gyrus, anterior cingulate cortex, right angular gyrus and left caudate nu-
cleus in the therapy group (Fig. 4A). There were no apparent increases
in MPFC functional connectivity changes in the control group. We ob-
served also a signiﬁcant decrease in functional connectivity of MPFC to
a boundary region of insula and frontal operculum in the therapy
group. Therewere no apparent decreases inMPFC functional connectiv-
ity in the control group (Fig. 4B).
Secondly, using seizure frequency changes as a regressor within
neuroimaging analyses, we tested how and where changes of MPFC
functional connectivity related to therapy-evoked changes in seizure
frequency. We observed increased functional connectivity between
MPFC and amygdala/bilateral temporal pole complex that correlated
signiﬁcantly with seizure reduction (Fig. 4C).Please cite this article as: Nagai, Y., et al., Epileptic Seizures are Reduced b
limbic Connectivity: A Controlled Tr..., EBioMedicine (2017), https://doi.oThis result links the reduction in seizure frequency in patients with
temporal lobe epilepsy to the enhancement of functional connectivity
between MPFC and amygdala complex. For the limbic networks, seeds
were placed in the left and right amygdala separately (Supplementary
Fig. S4). Across all participants (main effect), the amygdala seeds
showed strong functional connectivity with each other, with striatal re-
gions, and with the anterior cingulate (p b 0.01 FWE). The left and right
network connectivity was symmetrical at visual inspection (Supple-
mentary Fig. S5).
We observed a signiﬁcant therapy-related (group × session interac-
tion, p b 0.05 FWE) increase in left amygdala functional connectivity
with left insula, primary motor cortex (M1) bilaterally, precuneus, and
right angular gyrus (Supplementary Fig. S6, A), with larger increases
in connectivity in the therapy group than in the controls. We tested
for similar therapy-related changes in the connectivity of the right
amygdala (Supplementary Fig. S6, B) There were signiﬁcant increases
in the functional connectivity of right amygdala with precuneus, left
primary motor cortex (M1), and lateral occipital cortex bilaterally in
the therapy group. The control group showed no change.
When looking at the association between changes in functional
connectivity and the magnitude of reductions in seizure frequency, sig-
niﬁcant results were only found for the right amygdala network. In par-
ticular, patients who showed the greatest seizure frequency reduction
also showed the greatest increase in right amygdala functional connec-
tivity with the orbitofrontal cortex (OFC: 18, 28,−20 MNI coordinate)
and the frontal pole (FP:−4, 56, 10) (Fig. 5A). This effectwas only pres-
ent in the therapy group (Fig. 6B lower panel). Interestingly, the OFC re-
gion expressing this signiﬁcant correlationwas encompassedwithin the
region described in a previous study (Nagai et al., 2004c) in which a
negative linear correlation was found between neural activity and skin
conductance level (Fig. 5B upper panel). This result links mechanistical-
ly the modulation of sympathetic tone using GSR biofeedback training
to sustained reduction of seizure frequency in patients with drug-
resistant TLE. Changes in right amygdala functional connectivity to
OFC and FP predicted reduction in seizure frequency changes, but not
changes in anxiety score or other psychological variables recorded
(Fig. 6A–C). Seizure frequency was uncorrelated with change with
these reported psychological symptoms.
4. Discussion
Autonomic biofeedback as a behavioral therapy for epilepsy is not
yet widely recognized. The present clinical trial demonstrates a signiﬁ-
cant beneﬁcial effect of this therapy in reducing the seizure frequency
in patients with drug-resistant TLE. Our neuroimaging analysis identi-
ﬁed response-related changes in fronto-limbic connectivity, providing
insight into likely neural mechanisms underlying the efﬁcacy of this
therapy.
These results are encouraging. However, the study also had some
limitations. Firstly, one might anticipate that seeing a therapist three
times a week for four weeks may evoke a placebo effect that in itself re-
duces seizures, and engender, in parallel, improvement-related changes
in functional neural connectivity. This argument could have been ad-
dressed by comparison with an active sham control group, rather than
a treatment as usual group. Nevertheless, our previous experience of
RCT using an active sham control for the same GSR biofeedback therapy
protocol demonstrated no reduction in seizure frequency within the
sham control group (in fact an increase) (Nagai et al., 2004b). This
strongly suggests that non-speciﬁc interaction with the therapist
could not alone account for the observed seizure reduction in the cur-
rent study. Our neuroimaging ﬁndings also consistent with therapy-
evoked changes in epilepsy-relevant neural circuitry associated with
autonomicmodulation, rather than a generic placebo response. Notably,
the observed changes in functional connectivity between OFC and me-
dial temporal lobe (amygdala), build on previously recognized tight
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Fig. 3. Percentage seizure frequency changes. % Seizure frequency changes after GSR biofeedback therapy in control and biofeedback groups. Percentage seizure frequency change= [(Post
averaged seizure frequency-baseline averaged seizure frequency)/baseline averaged seizure frequency] × 100. The averaged seizure frequency change of Control group=31.10% (SD=±
88.27, median = 0), Therapy group = 43.0% (SD =±32.12, median = 37.26).
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amygdala connectivity demonstrated the most seizure reduction. Thus
even without a sham intervention, the involvement of autonomic con-
trol centers, and the correlation with seizure reduction, suggest that
the brain changes observed in the therapy group are more attributable
to GSR biofeedback training than to non-speciﬁc therapeutic ‘placebo’
effects. Although the study faced these limitations, our report sheds
light on a relatively neglected area of behavioral therapy and the role
of autonomic function in epilepsy.
A second important limitation of this study is the pragmatic devia-
tion from complete randomization to the therapy and control groups.
As described, ‘geographical bias’ occurred on account of the heavy com-
mitment required to attend behavioral therapy sessions. Nevertheless,
the groups were well matched on demographic and clinical measures.
It is therefore very unlikely that the reported therapy effects on seizure
frequency or brain connectivity reﬂected this allocation bias.
An average seizure reduction of 43% was observed across the thera-
py group of patientswith drug-resistant TLE. After amonth of autonom-
ic biofeedback therapy, 45% of these patients reported seizure reduction
of N50%. These results are similar to those of the previous single-blinded
sham-controlled RCT (Nagai et al., 2004b) and independent studies
with open label (Micoulaud-Franchi et al., 2014) and case control
study (Kotwas et al., 2017).
We observed a trend towards an overall increase in seizure frequen-
cy in the control group. Three patients reported N100% increase during
the follow up period. However, themedian seizure frequency change in
the control groupwas 0% and therewere no patients who showed N50%
seizure reduction. Thus there was no evidence to suggest an impact of
study participation on seizure frequency in the control group. The
mean seizure frequency increased in this control group (+31%) by a
similar magnitude to increases observed following sham biofeedback
(+25%) (Nagai et al., 2004b). Overall, in comparison with other treat-
ments, the observed effects of GSR biofeedback in reducing seizure fre-
quency are favorable (45%–66% response rates across existing trials).
This compares to a 21–47% response rate for new anti-epileptic drugs
(Cramer et al., 2001), a 30–70% response rate reported for Vagus
Nerve Stimulation (Englot et al., 2011) and a 30–55% response rate for
the ketogenic diet (Neal et al., 2008). However, the greatest advantage
of autonomic biofeedback therapy is that the approach is primarily be-
havioral and the effects can persist, once necessary skills are acquired
after a month of therapy training, without a device (Nagai andPlease cite this article as: Nagai, Y., et al., Epileptic Seizures are Reduced b
limbic Connectivity: A Controlled Tr..., EBioMedicine (2017), https://doi.oTrimble, 2014). Patients continued to apply the skills they had learned
to increase sympathetic activity in their daily lives as a counter-
measure to seizures. No side effects are recorded for this autonomic bio-
feedback therapy over the last 20 years, suggesting that this non-
invasive behavioral intervention to enable patients with drug-resistant
epilepsy to control their seizures is also very well tolerated. The present
study reinforces motivation for a much larger multi-central clinical trial
to further consolidate the efﬁcacy of this new intervention.
In this study, we provide neuroscientiﬁc insight of how this therapy
works. Establishing the biological validity of behavioral therapies
through a comprehensive neuroscientiﬁc account is generally challeng-
ing, even for well-established methodologies proven through clinical
trials, such as cognitive behavioral therapy. The current study aimed
to describe the core neural mechanisms that might account for the efﬁ-
cacy of GSR biofeedback therapy. We demonstrated changes in fore-
brain neural functional connectivity following one month of active
GSR biofeedback therapy. Theory-driven studies have led to converging
empirical evidence linking the propensity for epileptic seizures to ab-
normalities in resting-state functional connectivity (Lemieux et al.,
2011; Tracy and Doucet, 2015). We tested for functional connectivity
changes with emphasis on dynamic coupling with MPFC, predicated
upon established neuroimaging evidence of close links between neural
activity in this brain region and tonic level of sympathetic arousal,
indexed byGSR (Nagai et al., 2004c). Observed changes in network con-
nectivitywere speciﬁc to the therapy group, with no signiﬁcant changes
observed in the control group. A month of training using GSR biofeed-
back engendered enhancement of functional connectivity between ven-
tral MPFC/OFC and brain regions implicated in executive control and
attentional regulation, notably medial/superior frontal gyrus, angular
gyrus, and anterior cingulate cortex (also implicated in autonomic con-
trol) (Critchley and Harrison, 2013).
A striking ﬁnding was the observed linear correlation between sei-
zure frequency reduction and enhancement of functional connectivity
between right amygdala and prefrontal cortex (orbitofrontal cortex,
OFC and frontal pole). This part of OFC was encompassed within the
area identiﬁed as a brain region where the activity inversely coupled
to GSR level (Nagai et al., 2004c). The ﬁnding is consistent with the no-
tion that autonomic biofeedback training with GSR, ultimately enabling
the volitional modulation of sympathetic tone, also consolidate a neural
network between OFC and amygdala. Although we observed a change
in functional connectivity, our ﬁnding has relevance to the structuraly Autonomic Biofeedback Therapy Through Enhancement of Fronto-
rg/10.1016/j.ebiom.2017.12.012
Fig. 4. Changes in neural connectivity to VMPFC after a month of therapy. A) Increased neural connectivity to ventromedial prefrontal Cortex (VMPFC) was found in left angular gyrus,
bilateral medial and superior frontal gyrus, anterior cingulate, caudate nucleus in the therapy group. B) Decreased connectivity to VMPFC was found in right insular however
signiﬁcance was marginal. There was no signiﬁcant neural connectivity changes found in control group. C) The seizure reduction was correlated with increased functional neural
connectivity between VMPFC and amygdala complex, left temporal pole/parahippocumpus. All results are signiﬁcant a p b 0.05, after FWE correction at cluster level.
7Y. Nagai et al. / EBioMedicine xxx (2017) xxx–xxxconnections underpinning this network to epilepsy. The ﬁber tract cou-
pling OFC has also an anatomical connection to amygdala, which is
termed as uncinate fasciculus (Von Der Heide et al., 2013). The integrity
of this white matter tract has established relevance to seizure propaga-
tion in TLE (Diehl et al., 2008; Lin et al., 2008; Von Der Heide et al.,
2013). We speculate that increased functional connectivity between
OFC and amygdala corresponding to efﬁcient information ﬂow through
the uncinate fasciculus, could have been achieved by GSR biofeedbackPlease cite this article as: Nagai, Y., et al., Epileptic Seizures are Reduced b
limbic Connectivity: A Controlled Tr..., EBioMedicine (2017), https://doi.otraining through the conjoint roles of amygdala and OFC in autonomic
regulation. Anatomically, the uncinate fasciculus splits into two
brancheswithin frontal lobe, where the larger branch terminateswithin
OFC and the smaller branch terminates within frontal pole (de Schotten
et al., 2012). Correspondingly, we also observed that a strengthening
connectivity between amygdala and the frontal pole was associated
with seizure reduction following the autonomic biofeedback therapy.
Resection of a speciﬁc white matter connection (uncinate fasciculus)y Autonomic Biofeedback Therapy Through Enhancement of Fronto-
rg/10.1016/j.ebiom.2017.12.012
Fig. 5. Changes in neural connectivity to Right Amygdala associated to reduction in seizure frequency and alteration in subjective feeling of anxiety. A) Two distinctive functional
connectivity changes to Right Amygdala was observed in Orbitofrontal Cortex (OFC) and Frontal Pole (FP). B) The identiﬁed OFC area is linked to the regulatory center of skin
conductance which was previously discovered. The amygdala-OFC connection linearly correlated with degree of seizure reduction. All results are signiﬁcant a p b 0.05, after FWE
correction at cluster level.
8 Y. Nagai et al. / EBioMedicine xxx (2017) xxx–xxxinﬂuences the outcome of surgery in patients with TLE, suggesting this
white matter tract to be epileptogenic (Keller et al., 2016). In TLE, func-
tional integrity of the uncinate fasciculus, as the anatomical conduit be-
tween frontal lobe and limbic system, is likely to underpin thePlease cite this article as: Nagai, Y., et al., Epileptic Seizures are Reduced b
limbic Connectivity: A Controlled Tr..., EBioMedicine (2017), https://doi.oexpression of neuropsychiatric features of the disorder. Impairment
and dysfunction of the uncinate fasciculus is associatedwith the expres-
sion of psychiatric disorders, including schizophrenia, psychopathy,
anxiety and antisocial personality disorders (Von Der Heide et al.,y Autonomic Biofeedback Therapy Through Enhancement of Fronto-
rg/10.1016/j.ebiom.2017.12.012
Fig. 6. Correlation between seizure reduction, neural connectivity changes and STAI score changes. Correlation of seizure frequency change and State and Trait Anxiety Inventory (STAI)
score was separately plotted with OFC cluster (A) and FP cluster (B). Both OFC cluster and PF cluster was correlated only with seizure frequency changes but not with changes in
psychological questionnaire (STAI score). C) The degree of correlation between seizure reduction and both OFC and FC was presented for both therapy and control group.
9Y. Nagai et al. / EBioMedicine xxx (2017) xxx–xxx2013). Although speculative, the psychiatric co-morbidity observed in
many patients with TLE may originate in changes in uncinate fasciculus
with recurrent epileptic seizures. An implication of the currentPlease cite this article as: Nagai, Y., et al., Epileptic Seizures are Reduced b
limbic Connectivity: A Controlled Tr..., EBioMedicine (2017), https://doi.obehavioral study is that there is plasticity in this functional connectivity
even in patientswith drug-resistant epilepsy thatmay represent a treat-
ment target for other interventions. Nevertheless, in this study we didy Autonomic Biofeedback Therapy Through Enhancement of Fronto-
rg/10.1016/j.ebiom.2017.12.012
10 Y. Nagai et al. / EBioMedicine xxx (2017) xxx–xxxnot observe a strong association between changes in amygdala func-
tional connectivity with OFC/Frontal pole and self-reported anxiety
symptoms, although such a relationship might be predicted (Makovac
et al., 2016; Kim andWhalen, 2009). Our analysis tested for linear asso-
ciations, therefore we could not exclude a more complex relationship
between functional connectivity and anxiety exists.
Our ﬁndings reinforce the accumulating independent evidence
supporting the effectiveness of autonomic biofeedback therapy in
reducing the frequency of epileptic seizures (Nagai et al., 2004b; Nagai
and Trimble, 2014; Micoulaud-Franchi et al., 2014; Kotwas et al.,
2017). Moreover, our study extends the theoretical and neuroscientiﬁc
understanding of body-brain interactions relevant to epilepsy manage-
ment, by providing fresh empirical data regarding the neural mecha-
nisms through which autonomic biofeedback training may promote
seizure reduction. These ﬁndings have practical implications. For the
therapy to attain broad impact, there is a need for greater patient access,
proof of cost-effectiveness and population-level evaluation of its efﬁca-
cy. One solution under development is the production of a digital online
(yet supervised) version of the therapy. Once available, this new thera-
py platform can be assessed using clinical trial methodology (double-
blinded randomized controlled) that more closely replicate sample
sizes and statistical approaches used in drug studies. Finally the strate-
gies developed by the therapist to enable the patient to transfer skills
learned through GSR biofeedback can apply as countermeasures for
seizure control in daily life. Autonomic biofeedback training usingGSRof-
fers a promising and potentially potent adjunctive non-pharmacological
means of reducing seizures in patients with drug-resistant epilepsy.
Moreover, we are deﬁning neural mechanisms that may have wider
relevance as biomarkers and treatment targets.Funding Source
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